A drug to halt the progression of Alzheimer’s disease will likely be approved within the next three years, and Alzheon’s ALZ-801 might be the leading candidate.
No new Alzheimer’s drugs have been approved in the past 17 years. Now, “After decades of little to no progress, there’s a clear path forward in targeting the toxic amyloid aggregates,” Martin Tolar, M.D., Ph.D., founder, president, and CEO of Alzheon, told BioSpace.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,